Scholarlink

<p>Clear cell renal cell carcinoma (ccRCC) is resistant to conventional radiotherapy and chemotherapy, creating an urgent need for novel therapeutic strategies. Although GABA transaminase (ABAT) is involved in metabolic reprogramming as reported, its precise function and molecular mechanisms in ccRCC remain unclear. Here, we demonstrate that ABAT overexpression suppresses tumor growth both in vitro and in vivo. Mechanistically, ABAT mediates the cGAS–STING signaling pathway, and interacts with protein arginine methyltransferase 5 (PRMT5), thereby enhances interferon signaling. Besides, ABAT was found to reduce the infiltration of regulatory T cells within the tumor microenvironment. Collectively, these results suggest that ABAT represents a potential therapeutic target in clear cell renal cell carcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gamma-aminobutyric acid transaminase mediates tumor suppression in renal cell carcinoma through the cGAS-STING–interferon-β axis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月11日

查看全文
  • Yi Feng,
  • Senming Cao,
  • Tianwei Cai,
  • Yin Lu,
  • Bin Jiang,
  • Zexuan Lv,
  • Jinlu Tang,
  • Fan Gao,
  • Xupeng Zhao,
  • Chunyu Liu,
  • Qi Wang,
  • Ji Feng,
  • Zheng Wang,
  • Qing Ai,
  • Qiang Cheng,
  • Wenmei Fan,
  • Hongzhao Li

摘要

Clear cell renal cell carcinoma (ccRCC) is resistant to conventional radiotherapy and chemotherapy, creating an urgent need for novel therapeutic strategies. Although GABA transaminase (ABAT) is involved in metabolic reprogramming as reported, its precise function and molecular mechanisms in ccRCC remain unclear. Here, we demonstrate that ABAT overexpression suppresses tumor growth both in vitro and in vivo. Mechanistically, ABAT mediates the cGAS–STING signaling pathway, and interacts with protein arginine methyltransferase 5 (PRMT5), thereby enhances interferon signaling. Besides, ABAT was found to reduce the infiltration of regulatory T cells within the tumor microenvironment. Collectively, these results suggest that ABAT represents a potential therapeutic target in clear cell renal cell carcinoma.